LLY vs OPRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
OPRX presents a complex profile with a stable Piotroski F-Score of 4/9 and a current price ($6.40) aligned almost perfectly with its Graham Number ($6.45). While the balance sheet is exceptionally clean with low debt (0.20 D/E) and high liquidity (3.04 Current Ratio), the company suffers from stagnant revenue growth (-0.20% YoY) and a severe technical downtrend. The massive discrepancy between the growth-based intrinsic value ($1.89) and the analyst target ($14.50) suggests a high-risk turnaround play rather than a stable value investment.
Compare Another Pair
Related Comparisons
LLY vs OPRX: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and OptimizeRx Corporation (OPRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.